HOUSTON — December 16, 2025 — Leads & Copy — FibroBiologics, Inc. (Nasdaq: FBLG) announced the closing of its registered direct offering priced at-the-market under Nasdaq rules, along with a concurrent private placement.
The offering involved 5,227,275 shares of common stock at $0.33 per share. In the concurrent private placement, the company issued unregistered warrants to purchase up to 5,227,275 shares at an exercise price of $0.33 per share. The gross proceeds from the offering totaled approximately $1.7 million before deducting fees and expenses.
The warrants will be exercisable upon stockholder approval of the issuance of shares and will expire five years after the approval date. If all warrants are exercised, the company could receive an additional $1.7 million. However, there is no guarantee that stockholder approval will be obtained or that the warrants will be exercised.
FibroBiologics intends to use the net proceeds for working capital and general corporate purposes.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The shares were offered under a shelf registration statement on Form S-3, which was initially filed with the SEC on February 3, 2025, and became effective on February 10, 2025. The offering was made via a prospectus and prospectus supplement, which were filed with the SEC. Copies are available on the SEC’s website or by contacting H.C. Wainwright & Co., LLC.
The unregistered warrants and related shares were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D. These securities have not been registered and may not be offered or sold in the United States without registration or an applicable exemption.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities.
Based in Houston, FibroBiologics is a clinical-stage biotechnology company focused on developing treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company holds over 270 patents issued and pending across various clinical pathways.
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
Source: FibroBiologics
